Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Celcuity Inc. (CELC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa for Planned Phase 1b/2 Clinical Trial"
08/10/2023 8-K Quarterly results
Docs: "Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates"
03/23/2023 8-K Quarterly results
Docs: "Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"
03/15/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease , dated this 13 day of March, 2023, is by and between West Glen Development I, LLC, a Minnesota limited liability company and Celcuity, Inc., a Delaware corporation , and amends that certain Commercial Lease agreement dated the 28 th day of September, 2017, and amended by that certain First Amendment to Lease dated July 28, 2020 and that certain Second Amendment to Lease dated July 19 th , 2021, and that certain Third Amendment to Lease dated July 27, 2022 by and between Landlord and Tenant with respect to that certain building located at 16305 – 36 th Avenue North, the City of Plymouth, Hennepin County, Minnesota. Unless otherwise indicated, the terms defined in the Lease Agreement shall have the same meanings when used herein. WHER..."
12/23/2022 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
11/10/2022 8-K Quarterly results
09/14/2022 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Departure of Directors or C...
Docs: "FIRST AMENDMENT TO REPRESENTATIVE’ S WARRANT This FIRST AMENDMENT TO REPRESENTATIVE’ S WARRANT is entered into as of September 13, 2022 between Celcuity Inc., a Delaware corporation , and Craig-Hallum Capital Group LLC . WHEREAS, in connection with the Company’ s initial public offering and that certain Underwriting Agreement, dated September 19, 2017, between the Company and Holder as representative of the several underwriters listed in Schedule I thereto, the Company issued Holder a Representative’ s Warrant dated September 22, 2017 to purchase 138,000 shares of the Company’ s common stock, par value $0.001 per share ; and WHEREAS, the Company and Holder desire to amend the terms of the Warrant to reduce the number of shares of Common Stock that Holder may purchase pursuant to exercise o..."
09/01/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/11/2022 8-K Quarterly results
07/29/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Third Amendment to Lease, by and between Celcuity Inc. and West Glen Development I, LLC"
05/19/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
Docs: "Celcuity Inc. Balance Sheets December 31, 2021 December 31, 2020 Assets Current Assets: Cash and cash equivalents $ 84,286,381 $ 11,637,911 Deposits 22,009 22,009 Deferred transaction costs 22,144 - Payroll tax receivable 298,764 190,000 Prepaid assets 722,677 317,040 Total current assets 85,351,975 12,166,960 Property and equipment, net 312,444 558,876 Operating lease right-of-use assets 241,901 230,911 Total Assets $ 85,906,320 $ 12,956,747 Liabilities and Stockholders’ Equity: Current Liabilities: Accounts payable $ 1,507,099 $ 217,377 Finance lease liabilities 5,850 5,810 Operating lease liabilities 189,858 187,518 Accrued expenses 802,893 774,612 Total current liabilities 2,505,700 1,185,317 Finance lease liabilities 2,449 8,299 Operating lease liabilities 61,771 60,861 Note payable, ..."
02/04/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "ADDITIONAL EXHIBITS"
08/09/2021 8-K Quarterly results
Docs: "Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
06/30/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/08/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Celcuity Reports Third Quarter 2020 Financial Results and Recent Business Highlights - New clinical trial collaborations with pharmaceutical companies on track to close - - Cash burn rate steady - - Cash and cash equivalents of $13.7 million as of September 30, 2020, which is expected to support operations through 2021 - - Conference Call on Monday, November 9th at 4:30pm - Minneapolis, Minnesota—November 9, 2020—Celcuity Inc. , a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the third quarter ended September 30, 2020 and summarized recent business progress. “During the third quarter, we continued to advance our collaboration di..."
08/10/2020 8-K Quarterly results
06/05/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "At Market Issuance Sales Agreement, between Celcuity Inc. and B. Riley FBR, Inc",
"Opinion of Fredrikson & Byron, P.A"
05/15/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
12/12/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Celcuity Presents Results at the 2019 San Antonio Breast Cancer Symposium Evaluating a Sub-Group of PIK3CA WT Breast Cancer Patients Who Have Hyperactive Signaling Tumors Responsive to PI3K Inhibitors Minneapolis, Minnesota – December 11, 2019 - Celcuity Inc. , a dynamic cellular analysis company developing diagnostic tests to identify new patient populations for targeted therapies, announced that it presented results from a study of its newly developed CELx PI3K Signaling Function Test at the 2019 San Antonio Breast Cancer Symposium on December 11, 2019. The CELx PI3K Test identifies HER2-negative breast cancer patients with hyperactive PI3K-involved signaling tumors that respond ex vivo to PI3K inhibitors. Currently, only breast cancer patients with PIK3CA-mutations are eligible to recei..."
12/05/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Celcuity Announces Appointment of Richard Buller to Board of Directors Minneapolis, Minnesota—December 5, 2019 —Celcuity Inc. a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today announced the appointment of Richard Buller, M.D., Ph.D. to Celcuity’s Board of Directors, effective December 3, 2019. “We are very pleased to have attracted Dr. Richard Buller, a proven oncology drug development leader, to join our Board. Richard’s experience leading oncology clinical development and translational medicine departments at major pharmaceutical companies will provide a valuable perspective to Celcuity. He has participated ..."
11/07/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy